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Background: Prostate cancer is one of the most common malignancies in men. The mucin 1 (MUC1) heterodimeric
oncoprotein is overexpressed in human prostate cancers with aggressive pathologic and clinical features, resulting in a
poor outcome. However, the functional role for MUC1 C-terminal domain (MUC1-C) in androgen-independent prostate
cancer occurrence and development has remained unclear.
Methods: Cell viability was measured by MTT assays. Western blot analysis was performed to measure the
phosphorylation and protein expression of SAPK/JNK and ERK1/2, and MUC1-C, NF-κB subunit p65 and p50. Exogenous
expression of MUC1-C, NF-κB subunit p65 was carried out by transient and electroporated transfection assays.
Results: We showed that curcumin inhibited the growth of androgen-independent prostate cancer cells and a synergy
was observed in the presence of curcumin and bicalutamide, the androgen receptor antagonist. To further explore the
potential mechanism underlining this, we found that curcumin increased the phosphorylation of ERK1/2 and SAPK/JNK,
which was enhanced by bicalutamide. In addition, curcumin reduced the protein expression of MUC1-C and NF-κB
subunit p65, which were abrogated in the presence of the inhibitors of MEK/ERK1/2 (PD98059) and SAPK/JNK (SP60015).
A further reduction was observed in the combination of curcumin with bicalutamide. Moreover, while exogenous
expression of MUC1-C had little effect on curcumin-reduced p65, the overexpression of p65 reversed the effect of
curcumin on MUC1-C protein expression suggesting that p65 is upstream of MUC1-C. Intriguingly, we showed that
exogenous expression of MUC1-C feedback diminished the effect of curcumin on phosphorylation of ERK1/2 and
SAPK/JNK, and antagonized the effect of curcumin on cell growth.
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Conclusion: Our results show that curcumin inhibits the growth of androgen-independent prostate cancer cells
through ERK1/2- and SAPK/JNK-mediated inhibition of p65, followed by reducing expression of MUC1-C protein.
More importantly, there are synergistic effects of curcumin and bicalutamide. The negative feedback regulatory
loop of MUC1-C to ERK1/2 and SAPK/JNK further demonstrates the role of MUC1-C that contributes to the overall
responses of curcumin. This study unveils the potential molecular mechanism by which combination of curcumin
with bicalutamide enhances the growth inhibition of androgen-independent prostate cancer cells.
Keywords: Androgen-independent prostate cancer cells, Curcumin, Bicalutamide, SAPK/JNK, NF-κB/p65, MUC1-CIntroduction
Prostate cancer is one of the most common cancer types
and the second leading cause of cancer related death in
men in the world [1, 2]. The androgen deprivation therapy
(ADT), which suppresses or reduces androgens binding to
the androgen receptor (AR), is a well-known treatment
strategy for advanced, recurrent and even metastatic pros-
tate cancer; however, the long term therapeutic outcomes
of ADT on prostate cancer remain uncertain, and are as-
sociated with considerable known adverse effects that
affect the quality of life in prostate cancer patients [3].
Also, development of resistance to ADT is a major obs-
tacle for the management of advanced prostate cancer [4].
Therapies with AR antagonists such as bicalutamide
(Casodex) and androgen withdrawal initially regress tu-
mors but development of various compensatory mecha-
nisms including AR bypass signaling leading to tumor
growth, and eventually develop more aggressive castration
resistant prostate cancer (CRPC) [5]. Therefore, search for
the novel therapeutic approaches based on various combi-
nations of anticancer drugs and procedures to minimize
the resistance in order to enhance the therapeutic efficacy
are strongly required. Curcumin, an active natural poly-
phenol derived from the root of Curcuma longa, has been
shown great potential as a novel therapeutic agent due to
its pharmacological safety and efficacy in treating a wide
variety of cancers [6, 7]. These facts, tested and confirmed
in many different cancer types [8], have paved the way for
research aimed at elucidating the potential beneficial ef-
fects of combining curcumin and various anti-cancer
drugs in order to establish more efficient and less toxic
cancer treatment modalities.
Cell surface-associated mucin 1 (MUC1) (previously
known as PUM, MCKD1), a highly glycosylated trans-
membrane heterodimeric protein and a transmembrane
member of the mucin family, is highly expressed in vari-
ous human malignant tumors including prostate cancers
and is correlated with a poor prognosis [9, 10]. MUC1 cyto-
plasmic tail can interact with many signaling pathways, and
act as a co-transcription factor to activate various genes in-
volved in tumor progression and metastasis. In many tumor
types, expression of MUC1 correlates with aggressive,
metastatic phenotype, limited response to therapy and poorsurvival [10, 11]. The MUC-1 C-terminal subunit
(MUC1-C) is a single-pass transmembrane protein that
interacts with receptor tyrosine kinases, such as epider-
mal growth factor receptor (EGFR) and others, at the
cell membrane and contributes to activation of other
kinase signaling pathways that induce proliferation and
tumor growth [12–14]. MUC1-C also binds directly to
nuclear factor NF-kappaB (NF-κB) p65 and promotes
NF-κB-mediated gene transcription [9]. Thus, mucins
including MUC1-C are considered important markers
for early diagnosis and targeted therapy due to their
unique expression pattern during cancer progression.
Studies have provided substantial evidence for the in-
volvement of transmembrane MUC1-C in altered cell
signaling, tumor growth, and metastasis [15, 16].
In this study, we explored the potential mechanism by
which combination of curcumin with bicalutamide in
the inhibition growth of androgen-independent prostate
cancer cells.
Materials and methods
Cell culture and chemicals
The prostate cancer cell lines (PC3, DU145, LNCaP) were
obtained from the Sun Yat-sen Memorial Hospital, Sun
Yat-sen University, Guangzhou, China. All cell lines
have been tested and authenticated for absence of
Mycoplasma, genotypes, drug response, and morph-
ology in the Laboratory. Cells were grown in F-12K or
DMEM (1:1) medium (obtained from GIBCO, Life
Technologies, Grand Island, NY, USA) with supple-
mented 10 % fetal bovine serum. The polyclonal anti-
body against both MUC1 and MUC1-C (Cat No.
ab109185) was obtained from Abcam (Cambridge, MA,
USA). The antibodies against p65 (Cat No. 8242), total
extracellular signal-regulated kinase1/2 (ERK1/2) (Cat
No. 4695), stress-activated protein kinase/c-Jun N-
terminal kinase (SAPK/JNK) (Cat No. 9258) and the
phosphor-forms (Cat No. 4370 and 4668) were pur-
chased from Cell Signaling Technology Inc (Beverly,
MA, USA). Curcumin, PD98059 [(MAPK extracellular
signaling-regulated kinase (ERK) kinase (MEK)/ERK inhibi-
tor] and SP600125 (SAPK/JNK inhibitor) were obtained
from Sigma-Aldrich (St. Louis, MO, USA).
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The detailed procedure was reported previously [17, 18].
Briefly, protein concentrations were determined by the
Bio-Rad protein assay. Equal amounts of protein from
whole cell lysates were solubilized in 5 × SDS-sample
buffers and separated on 12 % SDS polyacrylamide gels.
Membranes were incubated with antibodies against
MUC1-C, p65, the phosphor and total ERK1/2, and SAPK/
JNK. The membranes were washed and incubated with a
secondary antibody raised against rabbit IgG conjugated to
horseradish peroxidase (Cell Signaling Technology, Inc.,
Beverly, MA, USA). The membranes were washed again
and transferred to freshly made ECL solution (Immobilon
Western; Millpore, Billerica, MA, USA), followed by ob-
serving the signals under the Molecular Imager ChemiDoc
XRS Gel Imagine System (Bio-Rad, Hercules, CA, USA)
and documenting the results.
Cell viability assay
Cell viability was measured using the 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) assay [18]. Briefly, prostate cancer cells were
harvested, counted and seeded in a 96-well microtitre
plate. The cells were treated with increasing concentrations
of curcumin for up to 72 hrs. After incubation, 20 μl MTT
solution (5 g/L) was added to each well and prostate cancer
cells were incubated at 37 °C for additional 4 h. Supernatant
was removed, then 200 μL solvent dimethyl sulfoxide was
added to each well and oscillated for 10 min. Absorbance at
490 nm was determined through the use of ELISA reader
(Perkin Elmer, Victor × 5, Waltham, MA, USA). Cell viabil-
ity (% of control) was calculated as (absorbance of test sam-
ple/absorbance of control) × 100 %.
Transient transfection assay
The cells were seeded in 6-well dishes and grown to 50–
60 % confluence. The control or MUC1-C and p65 overex-
pression vectors (pCMV6-AC-MUC1, pCMV6-AC-p65)
were obtained from OriGene Technologies, Inc. (Rockville,
MD, USA). Briefly, cells were seeded in 6-well dishes and
grown to 50–60 % confluence. For each well, 2 μg of con-
trol (pCMV6-AC) and MUC1-C and p65 plasmid DNA
constructs were transfected into the cells using Lipofecta-
mine 3000 reagent (Life Technologies, Grand Island, NY,
USA) for up to 30 h based on the instruction from the pro-
vider, followed by treating with curcumin for an additional
24 or 48 h for other experiments.
Statistical analysis
Data are presented as mean ± SD from three independent
experiments with triplicates. Statistical significance was de-
termined with Student's t test (two-tailed) comparison be-
tween two groups of data set. All statistical analyses were
performed using GraphPad Prism 5 software (GraphPadSoftware, Inc., La Jolla, CA, USA). Asterisks shown in the
figures indicate significant differences of experimental
groups in comparison with the corresponding control con-
dition (P < 0.05, see figure legends).
Results
The effect of curcumin and bicalutamide on growth of
prostate cancer cells
We first examined the effect of curcumin on prostate can-
cer cell growth. We showed that curcumin inhibited the
growth of multiple prostate cancer cell lines in the time-
and dose-dependent manner with significant effect most
observed at 40 μM at 48 h (Fig. 1a). Note that low dose
showing significant response were also seen in one
androgen-dependent prostate cancer cell (LNCaP) com-
pared to other two androgen-independent prostate cancer
cell lines (PC3 and DU145). We also demonstrated that
bicalutamide, an androgen receptor antagonist, inhibited
cell growth in dose- and time-dependent fashion in PC3
and LNCaP cells. Note that the inhibitory effect of bicalu-
tamid was different in LNCaP and PC3 cells; lower dose
and shorter time were observed in LNCaP cells (10 μM at
24 h), whereas high doses and longer time were found in
PC3 (30 μM, 72 h) (Fig. 1b) and DU145 cells (not shown).
Interestingly, while bicalutamide alone at lower doses (e.g.,
10–20 μM) had no effect on androgen-independent pros-
tate cancer cell growth inhibition, combination of curcu-
min with bicalutamide showed a significant inhibition of
cell growth in not only androgen-dependent but also
androgen-independent prostate cancer cells (Fig. 1c). This
suggested a potential new mechanism by which the com-
bination of curcumin and bicalutamide enhanced the
growth inhibition in androgen-independent prostate can-
cer cells.
Curcumin and bicalutamide increased phosphorylation of
ERK1/2 and SAPK/JNK
We then explored the potential signaling that may be in-
volved in the inhibitory response by curcumin and bica-
lutamide in androgen-independent prostate cancer cells.
We showed that curcumin increased the phosphoryl-
ation of ERK1/2 and SAPK/JNK in a time-dependent
fashion with significant induction observed at 4–8 h in
PC3 and DU145 cells (Fig. 2a, b). Furthermore, combin-
ation of curcumin with bicalutamide further enhanced
the phosphorylation of ERK1/2 and SAPK/JNK in PC3
and DU145 cells (Fig. 2c, d).
The effect of curcumin and bicalutamide on protein
expression of p65 and MUC1-C through activation of
MEK/ERK/12 and SAPK/JNK
Next, we further examined the potential molecular mech-
anism affected by curcumin in the presence or absence of
bicalutamide. We showed that curcumin reduced the
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Fig. 1 The effect of curcumin and bicalutamide on growth of prostate cancer cells. a Prostate cancer cells (PC3, DU145 and LNCaP) were treated
with increased concentrations of curcumin for up to 72 h to examine the cell viability. b Prostate cancer cells (PC3 and LNCaP) were treated with
increased concentrations of bicalutamide for up to 72 h to examine the cell viability c PC3, DU145 and LNCaP cells were treated with curcumin
(40 μM) and bicalutamide (30 μM) for 48 h to examine the cell viability. The cell viability was determined using the MTT assay as described in the
Materials and Methods section and was expressed as percentage of control in the mean ± SD of three separate experiments. *indicates significant
difference as compared to the untreated control group (P < 0.05). **Indicates significant difference from curcumin treated alone (P < 0.05)
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a membrane-anchored mucin, in the dose-dependent
manner in PC3 and DU145 cells (Fig. 3a). Note that cur-
cumin had no effect on p50 protein expression (Fig. 3a).
Interestingly, the inhibitors of MEK/ERK1/2 (PD98059)
and SAPK/JNK (SP60015) blocked the effect of curcumin
on both p65 and MUC1-C protein expression (Fig. 3b, c).
More importantly, we found that combination of curcu-
min with bicalutamide further significantly reduced the
protein expression of p65 and MUC1-C suggesting a syn-
ergy in this process (Fig. 3d).Exogenous expression of p65 abrogated the effect of
curcumin on MUC1-C expression and cell growth
inhibition
Moreover, we tested the role of p65 in this process;
we showed that exogenous expression of p65 blocked
the effect of curcumin on MUC1-C expression in
PC3 and DU145 cells (Fig. 4a, b); this suggested
that p65 is an upstream of MUC1-C. In addition,
we found that overexpression of p65 reversed
curcumin-inhibited growth in PC3 and DU145 cells
(Fig. 4c, d).
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Fig. 2 Curcumin and bicalutamide increased phosphorylation of ERK1/2 and SAPK/JNK. a-b PC3 and DU145 cells were treated with curcumin
(40 μM) in the indicated times, and cell lysate was harvested and the expression of the phosphorylated or total protein of ERK1/2 and SAPK/JNK
were measured by Western blot analysis using corresponding antibodies. GAPDH was used as loading control. c-d PC3 and DU145 cells were
treated with curcumin (40 μM) and bicalutamide (30 μM) for 8 h. Afterwards, the phosphorylation and expression of ERK1/2 and SAPK/JNK were
detected by Western blot. Values in bar graphs were given as the mean ± SD from three independent experiments performed in triplicate.
*indicates significant difference as compared to the untreated control group (P < 0.05). **Indicates significant difference from curcumin treated
alone (P < 0.05)
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attenuated the effect of curcumin on cell growth inhibition
and phosphorylation of ERK1/2 and SAPK/JNK
To further determine the role of MUC1-C in this process,
we transfected the exogenous expression vector of MUC1-
C into the cells and found that, while overexpression of
MUC1-C had no effect on curcumin-reduced p65 protein
expression in PC3 and DU145 cells (Fig. 5a), it significantly
antagonized the effect of curcumin on cell growth inhib-
ition (Fig. 5b). This result indicated the critical role of
MUC1-C in this process. Interestingly, exogenous expres-
sion of MUC1-C significantly attenuated the curcumin-induced phosphorylation of SAPK/JNK and ERK1/2 in PC3
and DU145 cells (Fig. 5c).
Discussion
Majority of advanced prostate cancers are sensitive to an-
drogen deprivation therapy in the first beginning, then sub-
sequently progress to the CRPC. The reasons remain
unknown. Because of the limitations of current therapeutic
approaches, many patients die of recurrent and metastatic
diseases. The combination with anti-inflammatory and
other adjuvant therapies present a very promising treat-
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Fig. 3 The effect of curcumin and bicalutamide on protein expression of p65 and MUC1-C through activation of ERK/12 and SAPK/JNK. a PC3
and DU145 cells ells were exposed to increased concentration of curcumin for 24 h. Afterwards, the expression of p65 and MUC1-C proteins was
detected by Western blot. b-c PC3 and DU145 cells were treated with PD98059 (10 μM) and SP600125 (20 μM) for 2 h before exposure of the cells to
curcumin (40 μM) for an additional 24 h. Afterwards, the expression of p65 and MUC1-C protein were detected by Western blot using antibodies
against p65 and MUC1-C. The bar graphs represent the mean ± SD of p65 or MUC1-C /GAPDH of three independent experiments. d, PC3 and DU145
cells were treated with curcumin (40 μM) and bicalutamide (30 μM) for 24 h. Afterwards, the expression of p65 and MUC1-C protein were detected by
Western blot using antibodies against p65 and MUC1-C. Values in bar graphs were given as the mean ± SD from three independent experiments
performed in triplicate. *indicates significant difference as compared to the untreated control group (P < 0.05). **Indicates significant difference from
curcumin treated alone (P < 0.05)
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cluding prostate cancer cells, and involves in multiple
signaling and potential targets [6, 7, 19]. However, the
detailed molecular mechanisms underlining suppres-
sion of androgen-independent prostate cancer cell
growth still remain to be elucidated. In this study, we
demonstrated not only a significant inhibition of
growth of prostate cancer cells by curcumin, but more
importantly, a synergistic effect observed in combin-
ation of curcumin with bicalutamide, an androgenreceptor antagonist, in androgen-independent prostate
cancer cells. These findings implied a potential new
mechanism for this synergy that was AR-unrelated. The
molecular mechanisms by which curcumin inhibited
growth of androgen-dependent and -independent pros-
tate cancer cells were reported in other studies demon-
strating that pathways and transcription factors other
than AR-mediated and -regulated downstream genes
were involved in this process [20–22]. However, more
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Fig. 4 Exogenous expression of p65 abrogated the effect of curcumin on MUC1-C expression and cell growth inhibition. a-b PC3 and DU145 cells
were transfected with the control (pCMV6) or expression constructs of p65 for 24 h before exposing the cells to curcumin for an additional
24 h. Afterwards, p65 and MUC1-C protein expression were determined by Western blot. c-d PC3 and DU145 cells were transfected with the
control (pCMV6) or expression construct of p65 for 24 h before exposing the cells to curcumin for an additional 48 h. Afterwards, the cell viability
was determined using the MTT assay as described in the Materials and Methods section and was expressed as percentage of control in the mean ± SD
of three separate experiments. Insert on the upper panel represented the protein levels of p65 as determined using Western blot. β-actin was used as
internal control. Values in bar graphs were given as the mean ± SD from three independent experiments performed in triplicate. *Indicates significant
difference as compared to the untreated control group (P < 0.05). **Indicates significant difference from curcumin treated alone (P < 0.01)
Li et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:46 Page 7 of 11In this study, we demonstrated the role of SAPK/JNK
and MEK/ERK1/2 signaling pathways in mediating the ef-
fect of curcumin and bicalutamide on controlling
growth of androgen-independent prostate cancer cells.
The activation of these kinases by curcumin or/and
bicalutamide has been shown in other studies implicat-
ing in the regulation of other gene expression and sub-
sequent cellular responses [23–28]. Consistent with
ours, one report showed that activation of SAPK/JNK was
involved in the curcumin-triggered intrinsic apoptotic
pathway in cardiac myoblasts [23]. Also, activation of
MEK/ERK1/2 pathway mediated in curcumin-induced cell
cycle arrest and apoptosis in human gastric cancer cells
[25]. We noticed that opposite results were also reportedin other cell system [29]. It was possible that the different
environment contexts, cell lines used, and other unknown
factors were account for this discrepancy. Thus, more
studies are required to further confirm this. Findings from
other studies including gene deletion data indicated the
conflicting results in essence that turn MEK/ERK1/2 and
SAPK/JNK functions from oncogene to tumor suppressor,
which could suggest the possible dual functions of these
kinases (pro-oncogene or tumor suppressor) [30–32].
Therefore, the insight true role of SAPK/JNK and MEK/
ERK1/2 signaling pathways in triggering cancer cell differ-
entiation, senescence, apoptosis, and survival appeared to
be context dependent and more complicated, which needs
to be clarified in the future.
DU145
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Fig. 5 Overexpression of MUC1-C attenuated the effect of curcumin on cell growth inhibition and curcumin-induced phosphorylation of ERK1/2
and SAPK/JNK. a PC3 and DU145 cells were transfected with the control (pCMV6) or expression constructs of MUC1-C for 24 h before exposing
the cells to curcumin for an additional 24 h. Afterwards, p65 and MUC1-C protein expression were determined by Western blot. b PC3 and
DU145 cells were transfected with the control (pCMV6) or expression constructs of MUC1-C for 24 h before exposing the cells to curcumin for an
additional 48 h. Afterwards The cell viability was determined using the MTT assay as described in the Materials and Methods section. Insert on
the upper panel represented the protein levels of MUC1-C as determined by Western blot. β-actin was used as internal control. Values in bar
graphs were given as the mean ± SD from three independent experiments performed in triplicate. *Indicates significant difference as compared
to the untreated control group (P < 0.05). **Indicates significant difference from curcumin treated alone (P < 0.01). c PC3 and DU145 cells were
transfected with the control (pCMV6) or expression constructs of MUC1-C for 24 h before exposing the cells to curcumin for an additional 8 h.
Afterwards, p-SAPK/JNK and p-ERK1/2 were determined by Western blot. d The diagram the shows that curcumin inhibits the growth of
androgen-independent prostate cancer cells through ERK1/2 and SAPK/JNK-mediated inhibition of p65, followed by reducing expression of
MUC1-C. There is a synergy of curcumin and bicalutamide. The negative feedback regulatory loop of MUC1-C to ERK1/2 and SAPK/JNK signaling
pathways also adds the important role of MUC1-C in mediating the overall responses of curcumin
Li et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:46 Page 8 of 11To further explore the potential mechanism underlin-
ing the aforementioned, we tested the involvement of
MUC1-C. Our results indicated the critical role of
MUC1-C in mediating the effect of curcumin on inhib-
ition of growth of androgen-independent prostate cancer
cells. Consistent with this, other studies were observed
the similar findings and suggested that MUC1 including
its subunits (e.g., MUC1-C) could be a potential targetof curcumin in the treatment of prostate and breast can-
cer cells [33, 34]. Furthermore, we demonstrated an im-
portant role of NF-κB/p65 that may involve in the
effects of curcumin on MUC1-C expression and prostate
cancer cell growth. Curcumin was shown to be a strong
inhibitor of NF-κB activity and its inhibitory effect on
NF-κB related pathways led to enhance the cytotoxicity
of chemotherapeutic agents in prostate cancer cells [35].
Li et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:46 Page 9 of 11Moreover, reported data have demonstrated the link of
MUC1-C and NF-κB signaling in other studies [36, 37].
Cancer cells are dependent on intact MUC1-C function
for constitutive activation of the canonical NF-κB path-
way and cancer cell growth, and survival [36, 37].
MUC1-C is a direct activator of NF-κB/p65 and that an
inhibitor of MUC1 function is effective in blocking acti-
vation of the NF-κB pathway in nonmalignant epithelial
cells [36, 37]. Our results implied that MUC1-C was
downstream of NF-κB. Consistent with this, early study
showed that MUC1 promoter region contained NF-κB/
p65 binding site that mediated the proinflammatory
cytokines-induced MUC1 promoter activity and gene ex-
pression in normal breast epithelia and breast cancer
cells [38]. Thus, the function and regulation of NF-κB/
p65-MUC1-C complexes are more complicated than we
could think. Nevertheless, we reasoned that regulation
of p65 played a crucial role in mediating curcumin-
inhibited MUC1-C expression in androgen-independent
prostate cancer cells.
We also observed the involvement of activation of MEK/
ERK1/2 and SAPK/JNK signaling pathways in the regula-
tion of p65 and MUC1-C affected by curcumin. The links
of these kinases to the regulation of NF-κB and MUC1-C
have been shown in other studies, suggesting that blockade
of these kinases could reduce expression of MUC1 in sev-
eral cell systems [12, 39–41]. More interestingly, we also
showed the negative feedback regulation of ERK1/2 and
SAPK/JNK by MUC1-C. These signaling axes formed a bi-
directional feedback loop to mediate curcumin-inhibited
prostate cancer proliferation. The feedback regulation cir-
cuit of kinases with other genes/proteins was reported in
other studies demonstrating relative common autocrine or
paracrine physiopathological phenomena [42, 43]. One
study found that sustained activation of SAPK/JNK inhib-
ited NF-κB signaling via a feedback loop mechanism that
led to an alteration in the transcription of the NF-κB-
induced apoptotic gene in immortalized renal proximal
tubular epithelial cells [44]. More experiments are war-
ranted to better elucidate the in-depth mechanism for these
unexplored complicated regulatory circuit.
More importantly, we demonstrated a synergy of com-
bination of curcumin and bicalutamide, the androgen re-
ceptor antagonist, in the inhibition of p65, MUC1-C and
androgen-independent prostate cancer cell growth, imply-
ing that signaling and mechanisms other than through the
AR-mediated regulatory pathways and genes contributed
to the overall enhanced effects. On the other hand, this
also suggested the potential new mechanism of bicaluta-
mide in controlling androgen-independent prostate cancer
cell growth. Bicalutamide was found to inhibit androgen-
independent prostate cancer cell growth appeared through
AR-independent pathways [45, 46]. One study showed
that combination of bicalutamide with other therapeuticagents enhanced the CRPC growth inhibition via up-
regulation of insulin-like growth factor-binding protein
3 (IGFBP3) [47]. Also, previous study indicated that
MUC1-C subunit suppressed AR expression through a
posttranscriptional mechanism and resisted to bicalutamide
treatment in androgen-dependent prostate cancer cells, this
implied that inhibition of AR expression by MUC1-C led to
develop more aggressive androgen-independent phenotype
in prostate cancer cells that was sensitive to MUC1-C
inhibition [10]. Consequently, this may facilitate the thera-
peutic effects of bicalutamide. We reasoned that MUC1-C
could be a potential target of curcumin in suppression of
androgen-independent prostate cancer cell growth, and
inhibition of MUC1-C by curcumin sensitized the thera-
peutic effect of bicalutamide in prostate cancer cell growth.
A cell based morphology experiment showed that curcu-
min analogs or curcumin-anti-androgen conjugates dem-
onstrated more potent than bicalutamide alone in the
cytotoxic effects on LNCaP and PC-3 cells through sup-
pression of pseudopodia formation, which was highly
related to cell migration and tumor metastasis, other than
targeting AR [48]. Also, note that studies implicated the
dissected mechanisms by which using different anti-
androgen receptor compounds on affecting prostate
cancer invasion and metastasis, resulting in opposite
effects [49]; the potential risks of using these agents,
such as bicalutamide, among others, on prostate can-
cer metastasis require to be carefully evaluated. Thus,
additional studies are warranted to further explore
the combination (curcumin and bicalutamide) effects
on invasion and metastasis of androgen-independent
prostate cancer cells.Conclusion
This study shows that curcumin inhibits the growth of
androgen-independent prostate cancer cells through
MEK/ERK1/2 and SAPK/JNK-mediated inhibition of
p65, followed by reducing expression of MUC1-C pro-
tein. More importantly, there is a synergy of curcumin
and bicalutamide. The negative feedback regulatory loop
of MUC1-C to ERK1/2 and SAPK/JNK signaling path-
ways further added the important role of MUC1-C in
mediating to the overall responses of curcumin (Fig. 5d).
This study unveils the potential molecular mechanism
by which combination of curcumin and bicalutamide en-
hances the growth inhibition of androgen-independent
prostate cancer cells.
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